PL3786167T3 - Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie - Google Patents
Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanieInfo
- Publication number
- PL3786167T3 PL3786167T3 PL19791600.0T PL19791600T PL3786167T3 PL 3786167 T3 PL3786167 T3 PL 3786167T3 PL 19791600 T PL19791600 T PL 19791600T PL 3786167 T3 PL3786167 T3 PL 3786167T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical composition
- macrocyclic compound
- diaryl macrocyclic
- diaryl
- compound
- Prior art date
Links
- -1 Diaryl macrocyclic compound Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810377811 | 2018-04-25 | ||
| PCT/CN2019/083644 WO2019206069A1 (zh) | 2018-04-25 | 2019-04-22 | 一种二芳基巨环化合物、药物组合物以及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3786167T3 true PL3786167T3 (pl) | 2024-11-25 |
Family
ID=68294851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19791600.0T PL3786167T3 (pl) | 2018-04-25 | 2019-04-22 | Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12129258B2 (pl) |
| EP (1) | EP3786167B1 (pl) |
| JP (2) | JP7128345B2 (pl) |
| CN (1) | CN111902417B (pl) |
| ES (1) | ES2989075T3 (pl) |
| PL (1) | PL3786167T3 (pl) |
| WO (1) | WO2019206069A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3786167B1 (en) * | 2018-04-25 | 2024-08-21 | Primegene (Beijing) Co., Ltd. | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
| WO2021098703A1 (zh) | 2019-11-18 | 2021-05-27 | 南京明德新药研发有限公司 | 作为高选择性ros1抑制剂的化合物及其应用 |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| CN113004305B (zh) * | 2019-12-19 | 2024-04-09 | 赛诺哈勃药业（成都）有限公司 | 大环化合物及其制备方法和用途 |
| CN113121568A (zh) * | 2019-12-31 | 2021-07-16 | 成都倍特药业股份有限公司 | 一种大环结构化合物的盐及其制备方法 |
| JP2023528907A (ja) * | 2020-06-04 | 2023-07-06 | シンノハブ ファーマシューティカル カンパニー，リミティド | 大環状構造を有する化合物及びその使用 |
| CN114763360A (zh) * | 2021-01-15 | 2022-07-19 | 广州百霆医药科技有限公司 | 手性大环化合物作为蛋白激酶抑制剂及其用途 |
| US20240132517A1 (en) * | 2021-02-10 | 2024-04-25 | Goharmony Therapeutics (Shenzhen) Co., Ltd. | Macrocyclic compound, pharmaceutical composition, and use thereof |
| CN116063326B (zh) * | 2021-11-02 | 2025-08-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| WO2024199479A1 (zh) * | 2023-03-31 | 2024-10-03 | 北京普祺医药科技股份有限公司 | 一种大环化合物、药物组合物及其用途 |
| WO2025212729A1 (en) * | 2024-04-03 | 2025-10-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and their use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2952692C (en) | 2008-09-22 | 2020-04-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds |
| PT3372605T (pt) | 2008-10-22 | 2021-12-09 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| SMT201900203T1 (it) | 2010-05-20 | 2019-05-10 | Array Biopharma Inc | Composti macrociclici come inibitori di trk chinasi |
| PL3097107T3 (pl) | 2014-01-24 | 2020-01-31 | Turning Point Therapeutics, Inc. | Diarylowe związki makrocykliczne jako modulatory kinaz białkowych |
| PL3733187T3 (pl) * | 2015-07-21 | 2025-01-07 | Turning Point Therapeutics, Inc. | Chiralny makrocykl diarylowy i jego zastosowanie w leczeniu raka |
| CA3031100A1 (en) | 2016-07-28 | 2018-02-01 | Tp Therapeutics, Inc. | Macrocycle kinase inhibitors |
| PL3658148T3 (pl) | 2017-07-28 | 2024-10-07 | Turning Point Therapeutics, Inc. | Związki makrocykliczne i ich zastosowania |
| US10698033B2 (en) | 2017-12-21 | 2020-06-30 | Robert Bosch Battery Systems, Llc | Sensor fault detection using paired sample correlation |
| TW201932472A (zh) | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
| CA3093140A1 (en) | 2018-03-28 | 2019-10-03 | Fochon Pharmaceuticals, Ltd. | Macrocyclic compounds as trk kinases inhibitors |
| EP3786167B1 (en) | 2018-04-25 | 2024-08-21 | Primegene (Beijing) Co., Ltd. | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
| CN110577549A (zh) | 2018-06-08 | 2019-12-17 | 焦玉奇 | 大环化合物 |
| WO2021063276A1 (zh) | 2019-09-30 | 2021-04-08 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| BR112022017425A2 (pt) | 2020-03-02 | 2022-11-29 | Turning Point Therapeutics Inc | Usos terapêuticos de compostos macrocíclicos |
-
2019
- 2019-04-22 EP EP19791600.0A patent/EP3786167B1/en active Active
- 2019-04-22 WO PCT/CN2019/083644 patent/WO2019206069A1/zh not_active Ceased
- 2019-04-22 CN CN201980020599.6A patent/CN111902417B/zh active Active
- 2019-04-22 ES ES19791600T patent/ES2989075T3/es active Active
- 2019-04-22 JP JP2021508050A patent/JP7128345B2/ja active Active
- 2019-04-22 US US17/049,734 patent/US12129258B2/en active Active
- 2019-04-22 PL PL19791600.0T patent/PL3786167T3/pl unknown
-
2022
- 2022-06-22 JP JP2022100260A patent/JP2022126780A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3786167A1 (en) | 2021-03-03 |
| US12129258B2 (en) | 2024-10-29 |
| JP2022126780A (ja) | 2022-08-30 |
| EP3786167C0 (en) | 2024-08-21 |
| JP2021519828A (ja) | 2021-08-12 |
| US20220162218A1 (en) | 2022-05-26 |
| WO2019206069A1 (zh) | 2019-10-31 |
| JP7128345B2 (ja) | 2022-08-30 |
| ES2989075T3 (es) | 2024-11-25 |
| EP3786167A4 (en) | 2021-06-09 |
| EP3786167B1 (en) | 2024-08-21 |
| CN111902417A (zh) | 2020-11-06 |
| CN111902417B (zh) | 2023-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3786167T3 (pl) | Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie | |
| IL288816A (en) | Aminobenzazepine compounds, immunoconjugates and uses thereof | |
| IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
| SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
| IL291760A (en) | Aminobenzazepine, amide-linked immunoconjugates and uses thereof | |
| EP3706741A4 (en) | PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL287905A (en) | A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use | |
| ZA201906451B (en) | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | |
| EP3741374A4 (en) | MTOR-INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USES | |
| IL272446A (en) | Penta-condensed hexa-heterocyclic compounds, method for their preparation, drug combination and use thereof | |
| PT3580208T (pt) | Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro | |
| PT3421038T (pt) | Compostos de naftiridina, combinações médicas e sua utilização | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL311894B1 (en) | Antibiotic compounds, methods for their production, pharmaceutical compositions containing them and uses thereof | |
| SG11201908281VA (en) | Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof | |
| SG11202006994XA (en) | Antibacterial compounds, compositions thereof, and methods using same | |
| EP3722395A4 (en) | Anti-friction compound and anti-friction compound with the anti-friction compound | |
| IL276290A (en) | Heteroaryl compounds, their pharmaceutical preparations and their medical use | |
| EP3670500A4 (en) | CHEMICAL COMPOUND, PHARMACEUTICAL COMPOSITION OF IT, CORRESPONDING USE AND APPLICATION | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| SG11202105012VA (en) | Aromatic ring-linked dioxino-quinazoline or dioxino-quinoline compounds, compositions and use thereof | |
| SG11202104371XA (en) | 1,3,4-oxadiazolone compound and pharmaceutical | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| EP3677267A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF |